Tumor Necrosis Factor Inhibitor Drugs Market Outlook 2031
The global tumor necrosis factor inhibitor drugs market size was valued at USD 41.21 Billion in 2022 and is likely reach to USD 43.10 Billion by 2031, expanding at a CAGR of 0.5% during the forecast period, 2023–2031. The growth of the market is attributed to the increasing incidence of autoimmune diseases, new product launches and growing consumer awareness.
Rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and juvenile idiopathic arthritis (JIA) are all autoimmune diseases that cause severe pain. Many people with rheumatologic autoimmune disease go months or years without knowing what is causing their pain, and standard pain relievers like nonsteroidal anti-inflammatory drugs (NSAIDs) do not work as well as they should.
When a patient does not react to usual treatment, an autoimmune disease process should be suggested as a promising cause. Tumor necrosis factor (TNF) inhibitors are anti-inflammatory medications. Rheumatoid arthritis (RA), juvenile arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, ulcerative colitis (UC), and Crohn's disease are all disorders that are treated with them.
TNF blockers, biologic therapies, and anti-TNF drugs are all terms used to describe these tumor necrosis factor. TNF inhibitors are relatively new additions to the armamentarium of drugs used to treat autoimmune diseases.
In 1998, the FDA approved Remicade (infliximab) and Enbrel (etanercept) for the first time. Humira (adalimumab) received FDA approval in 2002, followed by Cimzia (certolizumab pegol) in 2008, and Simponi (golimumab) in 2009. Simponi Aria, a golimumab IV infusion formulation, was authorized in 2013.
Tumor necrosis factor inhibitors are laboratory produced antibodies from human or animal tissue. Antibodies are produced by the body to fight infections. When they are injected into the bloodstream, they trigger an immune system reaction that prevents inflammation. Tumor necrosis factor is a substance produced by the immune system (TNF). TNF levels are usually maintained by the body.
However, something goes wrong if the patient has an autoimmune condition like Rheumatoid arthritics. The body produces too much TNF, which causes inflammation. Your body can be harmed by excess inflammation. You may get pain, swelling, or become sick as a result of this. TNF actions are suppressed by these medicines. After their initial dose, most people feel much better in 2 to 4 weeks.
Your symptoms could improve even more after 3 to 6 months. Some TNF inhibitors are administered as shots under the skin, such as Cimzia, Humira, Enbrel, Erelzi, and Simponi. Infusions of Remicade, Inflectra, and Simponi Aria, a Simponi variant, are administered at a clinic or doctor's office.
TNF inhibitors may also be prescribed in conjunction with other medications such as methotrexate, prednisone, hydroxychloroquine (Plaquenil), leflunomide (Arava), or sulfasalazine (Azulfidine). Tumor necrosis factor inhibitor are proved to be beneficial in chronic pain management for certain autoimmune conditions.
Tumor Necrosis Factor Inhibitor Drugs Market Trends, Drivers, Restraints, and Opportunities
- Increasing incidence of autoimmune diseases around the world is projected to drive the market growth during the forecast period.
- Favorable reimbursement policies by governments are anticipated to fuel the market growth during the forecast period.
- Increasing geriatric population around the world is anticipated to spur the market the growth during the forecast period.
- Technological advancements and increased expenditure on healthcare are key factors driving the market growth during the forecast period.
- Growing consumer demand for cost effective treatment with improved safety and efficacy profiles are expected to drive the market growth during the forecast period.
- Rising consumer awareness worldwide regarding the benefits of tumor necrosis factor inhibitor drugs are anticipated to propel the market growth in the coming years.
- High cost of the TNF inhibitors drugs and stringent regulatory framework possess as key challenges that can hamper the market growth during the forecast period.
- Increased emphasis on R&D for novel drug development is projected to offer lucrative opportunities for the market players.
Scope of The Tumor Necrosis Factor Inhibitor Drugs Market Report
The report on the global tumor necrosis factor inhibitor drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Tumor Necrosis Factor Inhibitor Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Product (Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, and Biosimilars), Application (Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, and Others), Sales Channel (Hospital Pharmacies, Specialty Pharmacies, and Online Pharmacies)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; UCB S.A.; Novartis International AG; Pfizer, Inc.; Merck & co., Inc.
|
Tumor Necrosis Factor Inhibitor Drugs Market Segment Insights
Humira segment is expected to account for a key share of the market
Based on product, the tumor necrosis factor inhibitor drugs market is segmented into humira, enbrel, remicade, simponi/simponi aria, cimzia, and biosimilars. The humira segment is expected to account for a key share of the market during the forecast period owing to its cost effectiveness and efficacy.
Although Humira's patent in Europe ended in 2018, the product's patent exclusivity in the United States is retained until 2023. The loss of patent exclusivity is expected to result in lower sales, although Humira is expected to remain at the top of the TNF inhibitor market. Biosimilars are posing a severe challenge to biologics, owing to their low cost and consistent results in head-to-head clinical trials. Humira, Enbrel, and Remicade all have biosimilar versions in the market.
Rheumatoid arthritis segment is expected to constitute a key share of the market
Based on application, the tumor necrosis factor inhibitor drugs market is segmented into rheumatoid arthritis, psoriasis, psoriatic arthritis, crohn’s disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, and others. The rheumatoid arthritis segment is expected to constitute a key share of the market during the forecast period owing to increased product penetration and high treatment rate.
On the other hand, the psoriasis and psoriatic arthritis segment is anticipated to expand at a rapid pace during the forecast period owing to increasing disease prevalence, consumer awareness, and favorable reimbursement policies. Furthermore, favorable initiatives by public and private institutes for increasing consumer awareness is expected to drive the segment growth further.
Hospital pharmacies segment is expected to hold a key share of the market
Based on sales channel, the tumor necrosis factor inhibitor drugs market is segmented into hospital pharmacies, specialty pharmacies, and online pharmacies. The hospital pharmacies segment is expected to hold a key share of the market during the forecast period coming due to rising patient turnover in hospitals.
Rather than retail pharmacies, specialty pharmacies sell the majority of biologics and biosimilars. Specialty pharmacies have a number of advantages, including the ability to create disease-specific care plans that are tailored to each patient's needs, thereby addressing financial concerns while also improving outcomes.
Tumor Necrosis Factor Inhibitor Drugs Market Regional Outlook
North America is anticipated to dominate the market
On the basis of regions, the tumor necrosis factor inhibitor drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to existence of key players, effective government initiatives, favorable reimbursement policies, and a huge patient pool.
On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increased adoption of biosimilars in emerging economies such as China, India, and South Korea. Furthermore, regional demand is likely to be driven by overall economic development, improvements in healthcare facilities, more disposable income, and increased consumer awareness.
Segments
Product
- Humira
- Enbrel
- Remicade
- Simponi/Simponi Aria
- Cimzia
- Biosimilars
Application
- Rheumatoid Arthritis
- Psoriasis
- Psoriatic Arthritis
- Crohn’s Disease
- Ulcerative Colitis
- Ankylosing Spondylitis
- Juvenile Idiopathic Arthritis
- Hidradenitis Suppurativa
- Others
Sales Channel
- Specialty Pharmacies
- Online Pharmacies
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- AbbVie Inc.
- Amgen Inc.
- Johnson & Johnson Services, Inc.
- UCB S.A.
- Novartis International AG
- Pfizer, Inc.
- Merck & co., Inc.
Competitive Landscape
Key players competing in the tumor necrosis factor inhibitor drugs market include/are AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; UCB S.A.; Novartis International AG; Pfizer, Inc.; and Merck & co., Inc.
New products have a major clinical advantage over existing products in terms of safety and efficacy, or the end result, as regulatory procedures becoming stricter and competition intensifying. As a result, several head-to-head studies have been conducted comparing significant commercial medications like Humira and Remicade and novel treatments or late-stage pipeline prospects.
The superiority of performance is determined in these trials by a comparison of numerous metrics. Therefore, some of key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase/enhance their market shares.
For example, in May 2019, the US Food and Drug Administration approved the use of Eticovo (SB4), a biosimilar developed by Samsung Bioepis Co., Ltd. in South Korea. It is Enbreland's second biosimilar, and it's used to treat ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis, among other conditions.
Request For Customization
Enquiry Before Buying
Speak With Analyst
